Jyong Biotech (NASDAQ:MENS) Shares Up 8.3% – Still a Buy?

Shares of Jyong Biotech Ltd. (NASDAQ:MENS) shot up 8.3% during mid-day trading on Thursday . The company traded as high as $2.38 and last traded at $2.22. Approximately 207,455 shares traded hands during trading, an increase of 33% from the average daily volume of 156,337 shares. The stock had previously closed at $2.05.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jyong Biotech in a report on Friday, May 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Jyong Biotech presently has an average rating of “Sell”.

Jyong Biotech Stock Performance

The firm’s 50-day moving average price is $2.00 and its 200 day moving average price is $2.62.

Jyong Biotech (NASDAQ:MENS) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.02) EPS for the quarter.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC increased its stake in Jyong Biotech by 209.4% in the 4th quarter. Millennium Management LLC now owns 40,258 shares of the company’s stock valued at $159,000 after buying an additional 27,245 shares during the last quarter. Man Group plc purchased a new stake in shares of Jyong Biotech during the fourth quarter valued at approximately $56,000. Jane Street Group LLC purchased a new position in Jyong Biotech in the fourth quarter worth $275,000. Geode Capital Management LLC grew its stake in Jyong Biotech by 19.6% in the 4th quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock valued at $254,000 after purchasing an additional 10,538 shares during the period. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Jyong Biotech during the 4th quarter worth $49,000.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.